BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best-performing European stocks to invest in. On August 29, BeOne Medicines Ltd. (NASDAQ:ONC) stated that the Phase 1/2 research of sonrotoclax had reached its main objective of overall response rate in patients with relapsed or refractory mantle cell lymphoma. Photo by National Cancer Institute on Unsplash The trial showed clinically relevant responses in the extensively pretreated patient category. Promising outcomes were also observed for secondary go ...